Article

8 EVOLUTION OF TREATMENT-EMERGENT RESISTANT VARIANTS IN TELAPREVIR PHASE 3 CLINICAL TRIALS

2011-03-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 79516437-a0a4-54a4-b723-2d82d842a112
DOI: 10.1016/s0168-8278(11)60010-x

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

8 EVOLUTION OF TREATMENT-EMERGENT RESISTANT VARIANTS IN TELAPREVIR PHASE 3 CLINICAL TRIALSDOI 10.1016/s0168-8278(11)60010-xRead

Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical TrialsSemantic proximity Read

Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir.Semantic proximity Read

Many mutations in one clinical-trial basket.Semantic proximity Read

Genetic risks of antiviral nucleoside analogues – a surveySemantic proximity Read

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.Semantic proximity Read

COVID drug drives viral mutations - and now some want to halt its use.Semantic proximity Read

Treatment-Emergent Influenza Virus Polymerase Acidic Substitutions Independent of Those at I38 Associated With Reduced Baloxavir Susceptibility and Virus Rebound in Trials of Baloxavir Marboxil.Semantic proximity Read

Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.Semantic proximity Read

Incidence of virological failure and emergence of resistance with twice-daily vs every 8-h administration of telaprevir in the OPTIMIZE study.Semantic proximity Read

Drug resistance and treatment of experienced patients.Semantic proximity Read

Deep-Sequencing Analysis of the Gene Encoding the Hepatitis C Virus Nonstructural 3–4A Protease Confirms a Low Prevalence of Telaprevir-Resistant Variants at Baseline and the End of the REALIZE StudySemantic proximity Read

Development of Resistance-Associated Mutations After Sotrovimab Administration in High-risk Individuals Infected With the SARS-CoV-2 Omicron Variant.Semantic proximity Read